Rockwell Medical, Inc. (RMTI)
USD 0.93
(-7.0%)
USD 0.93
(-7.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 5.87 Million USD | 0.98% |
| 2022 | 5.81 Million USD | 42.64% |
| 2021 | 4.07 Million USD | 4.17% |
| 2020 | 3.91 Million USD | 7.3% |
| 2019 | 3.64 Million USD | -9.7% |
| 2018 | 4.03 Million USD | -47.12% |
| 2017 | 7.63 Million USD | -37.09% |
| 2016 | 12.14 Million USD | 54.24% |
| 2015 | 7.87 Million USD | 100.8% |
| 2014 | 3.92 Million USD | 40.02% |
| 2013 | 2.79 Million USD | 5.66% |
| 2012 | 2.64 Million USD | 5.81% |
| 2011 | 2.5 Million USD | -14.74% |
| 2010 | 2.93 Million USD | -4.9% |
| 2009 | 3.08 Million USD | -2.32% |
| 2008 | 3.16 Million USD | 23.55% |
| 2007 | 2.55 Million USD | -3.8% |
| 2006 | 2.66 Million USD | 29.65% |
| 2005 | 2.05 Million USD | 24.17% |
| 2004 | 1.65 Million USD | 22.38% |
| 2003 | 1.35 Million USD | -8.55% |
| 2002 | 1.47 Million USD | 38.44% |
| 2001 | 1.06 Million USD | 82.27% |
| 2000 | 585.12 Thousand USD | 46.28% |
| 1999 | 400 Thousand USD | 0.0% |
| 1998 | - USD | -100.0% |
| 1997 | 300 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 6.07 Million USD | 3.44% |
| 2024 Q2 | 5.88 Million USD | -3.13% |
| 2023 Q3 | 5.48 Million USD | -5.64% |
| 2023 FY | 5.87 Million USD | 0.98% |
| 2023 Q2 | 5.81 Million USD | 3.91% |
| 2023 Q1 | 5.59 Million USD | -3.77% |
| 2023 Q4 | 5.87 Million USD | 7.02% |
| 2022 FY | 5.81 Million USD | 42.64% |
| 2022 Q3 | 5.02 Million USD | -2.92% |
| 2022 Q1 | 5.53 Million USD | 35.7% |
| 2022 Q2 | 5.17 Million USD | -6.51% |
| 2022 Q4 | 5.81 Million USD | 15.82% |
| 2021 Q1 | 4.11 Million USD | 5.21% |
| 2021 FY | 4.07 Million USD | 4.17% |
| 2021 Q2 | 4.67 Million USD | 13.6% |
| 2021 Q4 | 4.07 Million USD | 1.19% |
| 2021 Q3 | 4.02 Million USD | -13.88% |
| 2020 Q4 | 3.91 Million USD | 0.93% |
| 2020 Q1 | 4.29 Million USD | 17.71% |
| 2020 Q2 | 4.55 Million USD | 6.16% |
| 2020 Q3 | 3.87 Million USD | -14.93% |
| 2020 FY | 3.91 Million USD | 7.3% |
| 2019 FY | 3.64 Million USD | -9.7% |
| 2019 Q3 | 3.58 Million USD | -9.8% |
| 2019 Q2 | 3.97 Million USD | -0.72% |
| 2019 Q4 | 3.64 Million USD | 1.77% |
| 2019 Q1 | 4 Million USD | -0.92% |
| 2018 Q4 | 4.03 Million USD | -13.08% |
| 2018 Q1 | 8.54 Million USD | 11.88% |
| 2018 Q2 | 4.51 Million USD | -47.1% |
| 2018 Q3 | 4.64 Million USD | 2.8% |
| 2018 FY | 4.03 Million USD | -47.12% |
| 2017 Q4 | 7.63 Million USD | -48.62% |
| 2017 Q2 | 13.77 Million USD | 2.63% |
| 2017 FY | 7.63 Million USD | -37.09% |
| 2017 Q1 | 13.42 Million USD | 10.54% |
| 2017 Q3 | 14.86 Million USD | 7.92% |
| 2016 Q2 | 11 Million USD | 20.14% |
| 2016 Q4 | 12.14 Million USD | 3.24% |
| 2016 FY | 12.14 Million USD | 54.24% |
| 2016 Q3 | 11.76 Million USD | 6.82% |
| 2016 Q1 | 9.16 Million USD | 16.41% |
| 2015 Q4 | 7.87 Million USD | 6.16% |
| 2015 Q1 | 5.19 Million USD | 32.54% |
| 2015 FY | 7.87 Million USD | 100.8% |
| 2015 Q2 | 6.31 Million USD | 21.54% |
| 2015 Q3 | 7.41 Million USD | 17.42% |
| 2014 Q1 | 2.9 Million USD | 3.94% |
| 2014 Q2 | 2.78 Million USD | -4.32% |
| 2014 Q3 | 2.98 Million USD | 7.09% |
| 2014 FY | 3.92 Million USD | 40.02% |
| 2014 Q4 | 3.92 Million USD | 31.48% |
| 2013 Q1 | 2.86 Million USD | 8.15% |
| 2013 Q4 | 2.79 Million USD | -0.52% |
| 2013 Q3 | 2.81 Million USD | -3.51% |
| 2013 FY | 2.79 Million USD | 5.66% |
| 2013 Q2 | 2.91 Million USD | 1.78% |
| 2012 Q1 | 2.41 Million USD | -3.75% |
| 2012 Q4 | 2.64 Million USD | -0.84% |
| 2012 Q3 | 2.67 Million USD | -3.26% |
| 2012 Q2 | 2.76 Million USD | 14.6% |
| 2012 FY | 2.64 Million USD | 5.81% |
| 2011 FY | 2.5 Million USD | -14.74% |
| 2011 Q4 | 2.5 Million USD | 12.06% |
| 2011 Q3 | 2.23 Million USD | -5.22% |
| 2011 Q2 | 2.35 Million USD | -15.26% |
| 2011 Q1 | 2.78 Million USD | -5.26% |
| 2010 FY | 2.93 Million USD | -4.9% |
| 2010 Q2 | 2.86 Million USD | 12.45% |
| 2010 Q1 | 2.54 Million USD | -17.55% |
| 2010 Q3 | 2.53 Million USD | -11.48% |
| 2010 Q4 | 2.93 Million USD | 15.87% |
| 2009 Q3 | 2.67 Million USD | -4.93% |
| 2009 Q1 | 2.81 Million USD | -10.94% |
| 2009 Q2 | 2.81 Million USD | -0.09% |
| 2009 Q4 | 3.08 Million USD | 15.47% |
| 2009 FY | 3.08 Million USD | -2.32% |
| 2008 FY | 3.16 Million USD | 23.55% |
| 2008 Q1 | 2.67 Million USD | 4.42% |
| 2008 Q3 | 3.16 Million USD | 16.74% |
| 2008 Q4 | 3.16 Million USD | -0.16% |
| 2008 Q2 | 2.71 Million USD | 1.51% |
| 2007 Q3 | 2.79 Million USD | -0.96% |
| 2007 FY | 2.55 Million USD | -3.8% |
| 2007 Q1 | 2.65 Million USD | -0.11% |
| 2007 Q2 | 2.82 Million USD | 6.18% |
| 2007 Q4 | 2.55 Million USD | -8.41% |
| 2006 Q3 | 2.54 Million USD | 0.09% |
| 2006 Q4 | 2.66 Million USD | 4.43% |
| 2006 Q1 | 2.21 Million USD | 7.8% |
| 2006 Q2 | 2.54 Million USD | 15.05% |
| 2006 FY | 2.66 Million USD | 29.65% |
| 2005 Q3 | 2.06 Million USD | -13.33% |
| 2005 Q2 | 2.37 Million USD | -10.2% |
| 2005 FY | 2.05 Million USD | 24.17% |
| 2005 Q1 | 2.64 Million USD | 60.36% |
| 2005 Q4 | 2.05 Million USD | -0.52% |
| 2004 Q4 | 1.65 Million USD | 14.94% |
| 2004 Q1 | 1.61 Million USD | 19.31% |
| 2004 Q2 | 1.43 Million USD | -11.03% |
| 2004 Q3 | 1.43 Million USD | 0.3% |
| 2004 FY | 1.65 Million USD | 22.38% |
| 2003 FY | 1.35 Million USD | -8.55% |
| 2003 Q1 | 1.53 Million USD | 3.71% |
| 2003 Q3 | 1.35 Million USD | -13.71% |
| 2003 Q2 | 1.56 Million USD | 2.53% |
| 2003 Q4 | 1.35 Million USD | -0.32% |
| 2002 Q1 | 1.47 Million USD | 38.08% |
| 2002 Q3 | 2.06 Million USD | -4.21% |
| 2002 Q4 | 1.47 Million USD | -28.63% |
| 2002 Q2 | 2.15 Million USD | 46.65% |
| 2002 FY | 1.47 Million USD | 38.44% |
| 2001 Q3 | 808.29 Thousand USD | 23.27% |
| 2001 Q1 | 622.42 Thousand USD | 6.38% |
| 2001 FY | 1.06 Million USD | 82.27% |
| 2001 Q4 | 1.06 Million USD | 31.95% |
| 2001 Q2 | 655.72 Thousand USD | 5.35% |
| 2000 Q3 | 526.45 Thousand USD | -12.67% |
| 2000 FY | 585.12 Thousand USD | 46.28% |
| 2000 Q1 | 578.8 Thousand USD | 44.7% |
| 2000 Q2 | 602.8 Thousand USD | 4.15% |
| 2000 Q4 | 585.12 Thousand USD | 11.14% |
| 1999 Q4 | 400 Thousand USD | 0.0% |
| 1999 Q2 | 300 Thousand USD | 0.0% |
| 1999 FY | 400 Thousand USD | 0.0% |
| 1999 Q1 | 300 Thousand USD | 0.0% |
| 1999 Q3 | 400 Thousand USD | 33.33% |
| 1998 Q2 | 300 Thousand USD | 0.0% |
| 1998 Q3 | 200 Thousand USD | -33.33% |
| 1998 Q4 | - USD | -100.0% |
| 1998 FY | - USD | -100.0% |
| 1998 Q1 | 300 Thousand USD | 0.0% |
| 1997 Q3 | 400 Thousand USD | 0.0% |
| 1997 FY | 300 Thousand USD | 0.0% |
| 1997 Q4 | 300 Thousand USD | -25.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Cosmos Health Inc. | 4.78 Million USD | -22.592% |
| Safety Shot Inc | 1.86 Million USD | -214.016% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 96.14% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 94.72% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 13.266% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 81.842% |
| Dynavax Technologies Corporation | 53.29 Million USD | 88.983% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 91.053% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 49.592% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 94.374% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -2.376% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -2.376% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -625.032% |
| Journey Medical Corporation | 10.2 Million USD | 42.475% |
| Alpha Teknova, Inc. | 11.59 Million USD | 49.362% |
| Procaps Group, S.A. | 96.83 Million USD | 93.937% |
| Theratechnologies Inc. | 6.06 Million USD | 3.215% |
| Harrow Health, Inc. | 10.86 Million USD | 45.974% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -115.925% |
| Biofrontera Inc. | 10.9 Million USD | 46.177% |
| DURECT Corporation | 2.21 Million USD | -164.579% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 92.416% |
| Cronos Group Inc. | 30.33 Million USD | 80.649% |
| OptiNose, Inc. | 8.05 Million USD | 27.086% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -587099900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -3.017% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 79.22% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -119.303% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -27.371% |
| Radius Health, Inc. | 278.64 Million USD | 97.893% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -75.607% |
| ProPhase Labs, Inc. | 3.84 Million USD | -52.851% |
| Phibro Animal Health Corporation | 265.91 Million USD | 97.792% |
| Procaps Group S.A. | 96.83 Million USD | 93.937% |
| Alvotech | 74.43 Million USD | 92.112% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.831% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 53.526% |
| SIGA Technologies, Inc. | 64.21 Million USD | 90.858% |
| Tilray Brands, Inc. | 252.08 Million USD | 97.671% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 85.315% |
| Shineco, Inc. | 1.58 Million USD | -269.588% |
| PetIQ, Inc. | 159.3 Million USD | 96.315% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 3942.831% |
| Incannex Healthcare Limited | -10.01 Million USD | 158.622% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 84.671% |
| Alimera Sciences, Inc. | 1.87 Million USD | -212.453% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 84.421% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -264.57% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -30.961% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -2208.219% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 43.439% |
| Hempacco Co., Inc. | 2.54 Million USD | -130.903% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 92.112% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 87.716% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 90.831% |
| Currenc Group, Inc. | 732.91 Thousand USD | -701.052% |
| Kamada Ltd. | 87.74 Million USD | 93.309% |
| Indivior PLC | 141.79 Million USD | 95.86% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -1118.454% |
| Flora Growth Corp. | 8.5 Million USD | 30.994% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -2208.219% |
| Evolus, Inc. | 10.99 Million USD | 46.618% |
| HUTCHMED (China) Limited | 50.25 Million USD | 88.318% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 94.453% |
| Akanda Corp. | 1.28 Million USD | -356.215% |